{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:29:34Z","timestamp":1791822574544,"version":"4.3.4"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T00:00:00Z","timestamp":1581033600000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"CureJM and the Bath Institute of Rheumatic Diseases"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>In order to address the reliability of commercial assays to identify myositis-specific and -associated autoantibodies, we aimed to compare the results of two commercial immunoassays with the results obtained by protein immunoprecipitation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Autoantibody status was determined using radio-labelled protein immunoprecipitation for patients referred to our laboratory for myositis autoantibody characterization. For each autoantibody of interest, the sera from 25 different patients were analysed by line blot (Euroline Myositis Antigen Profile 4, EuroImmun, L\u00fcbeck, Germany) and dot blot (D-Tek BlueDiver, Diagnostic Technology, Belrose, NSW, Australia). Sera from 134 adult healthy controls were analysed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall commercial assays performed reasonably well, with high agreement (Cohen\u2019s \u03ba &amp;gt;0.8). Notable exceptions were the detection of rarer anti-synthetases with \u03ba\u2009&amp;lt;\u20090.2 and detection of anti-TIF1\u03b3, where \u03ba was 0.70 for the line blot and 0.31 for dot blot. Further analysis suggested that the proportion of patients with anti-TIF1\u03b3 may recognize a conformational epitope, limiting the ability of blotting-based assays that utilize denatured antigen to detect this clinically important autoantibody. A false-positive result occurred in 13.7% of samples analysed by line blot and 12.1% analysed by dot blot.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The assays analysed do not perform well for all myositis-specific and -associated autoantibodies and overall false positives are relatively common. It is crucial that clinicians are aware of the limitations of the methods used by their local laboratory. Results must be interpreted within the clinical context and immunoprecipitation should still be considered in selected cases, such as apparently autoantibody-negative patients where anti-synthetase syndrome is suspected.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa021","type":"journal-article","created":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T15:11:08Z","timestamp":1580137868000},"page":"2109-2114","source":"Crossref","is-referenced-by-count":138,"title":["The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity"],"prefix":"10.1093","volume":"59","author":[{"given":"Sarah L","family":"Tansley","sequence":"first","affiliation":[{"name":"Department of Pharmacy and pharmacology, University of Bath, Bath, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danyang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and pharmacology, University of Bath, Bath, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe E","family":"Betteridge","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and pharmacology, University of Bath, Bath, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2765-658X","authenticated-orcid":false,"given":"Neil J","family":"McHugh","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and pharmacology, University of Bath, Bath, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,2,6]]},"reference":[{"key":"2020072516474519400_keaa021-B1","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jaut.2019.04.001","article-title":"Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients","volume":"101","author":"Betteridge","year":"2019","journal-title":"J Autoimmun"},{"key":"2020072516474519400_keaa021-B2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jaut.2017.06.007","article-title":"Autoantibodies in juvenile-onset myositis: their diagnostic value and associated clinical phenotype in a large UK cohort","volume":"84","author":"Tansley","year":"2017","journal-title":"J Autoimmun"},{"key":"2020072516474519400_keaa021-B3","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/art.38270","article-title":"Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis","volume":"66","author":"Aggarwal","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2020072516474519400_keaa021-B4","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/rheumatology\/kem045","article-title":"Anti-synthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia","volume":"46","author":"Betteridge","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"2020072516474519400_keaa021-B5","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1136\/ard.2008.097162","article-title":"Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis","volume":"68","author":"Betteridge","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2020072516474519400_keaa021-B6","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1136\/annrheumdis-2018-214690","article-title":"Comparison of autoantibody specificities tested by a line blot assay and immunoprecipitation-based algorithm in patients with idiopathic inflammatory myopathies","volume":"78","author":"Espinosa-Ortega","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2020072516474519400_keaa021-B7","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.pathol.2016.03.012","article-title":"Diagnostic performance of a commercial immunoblot assay for myositis antibody testing","volume":"48","author":"Bundell","year":"2016","journal-title":"Pathology"},{"key":"2020072516474519400_keaa021-B8","doi-asserted-by":"crossref","first-page":"R138","DOI":"10.1186\/ar4600","article-title":"Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study","volume":"16","author":"Tansley","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2020072516474519400_keaa021-B9","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1093\/rheumatology\/keu259","article-title":"Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset","volume":"53","author":"Tansley","year":"2014","journal-title":"Rheumatology"},{"key":"2020072516474519400_keaa021-B10","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3899\/jrheum.160871","article-title":"Anti-HMGCR autoantibodies in juvenile idiopathic inflammatory myopathies identify a rare but clinically important subset of patients","volume":"44","author":"Tansley","year":"2017","journal-title":"J Rheumatol"},{"key":"2020072516474519400_keaa021-B11"},{"key":"2020072516474519400_keaa021-B12","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/bjd.18133","article-title":"Utilization patterns and performance of commercial myositis autoantibody panels in routine clinical practice","volume":"181","author":"Gandiga","year":"2019","journal-title":"Br J Dermatol"},{"key":"2020072516474519400_keaa021-B13","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/practneurol-2017-001742","article-title":"Autoantibody testing in idiopathic inflammatory myopathies","volume":"19","author":"Rietveld","year":"2019","journal-title":"Pract Neurol"},{"key":"2020072516474519400_keaa021-B14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2016.02.017","article-title":"Testing for myositis specific autoantibodies: comparison between line blot and immunoprecipitation assays in 57 myositis sera","volume":"433","author":"Cavazzana","year":"2016","journal-title":"J Immunol Methods"},{"key":"2020072516474519400_keaa021-B15","doi-asserted-by":"crossref","first-page":"112661","DOI":"10.1016\/j.jim.2019.112661","article-title":"Evaluation of a novel particle-based assay for detection of autoantibodies in idiopathic inflammatory myopathies","volume":"474","author":"Cavazzana","year":"2019","journal-title":"J Immunol Methods"},{"key":"2020072516474519400_keaa021-B16","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/MD.0b013e31829d08f9","article-title":"The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies","volume":"92","author":"Rider","year":"2013","journal-title":"Medicine"},{"key":"2020072516474519400_keaa021-B17","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1002\/art.22164","article-title":"A novel autoantibody to a 155-kd protein is associated with dermatomyositis","volume":"54","author":"Targoff","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2020072516474519400_keaa021-B18","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/art.33403","article-title":"Myositis-specific anti-155\/140 autoantibodies target transcription intermediary factor 1 family proteins","volume":"64","author":"Fujimoto","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2020072516474519400_keaa021-B19","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1002\/art.38093","article-title":"Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1gamma","volume":"65","author":"Fiorentino","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2020072516474519400_keaa021-B20","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jdermsci.2016.09.013","article-title":"Enzyme-linked immunosorbent assays for detection of anti-transcriptional intermediary factor-1 gamma and anti-Mi-2 autoantibodies in dermatomyositis","volume":"84","author":"Fujimoto","year":"2016","journal-title":"J Dermatol Sci"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/59\/8\/2109\/33532488\/keaa021.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/59\/8\/2109\/33532488\/keaa021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T16:49:37Z","timestamp":1595695777000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/59\/8\/2109\/5728764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,6]]},"references-count":20,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,2,6]]},"published-print":{"date-parts":[[2020,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa021","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,8]]},"published":{"date-parts":[[2020,2,6]]}}}